Previous 10 | Next 10 |
Exact Sciences Announces Preliminary Fourth Quarter 2022 Results PR Newswire Preliminary fourth quarter highlights: Expected total fourth quarter revenue, excluding COVID - 19 testing, increased 28% compared to the fourth quarter 2021, with Screening revenue of $...
Summary As the woke mob’s fury grows, Tesla shares are down 70%, despite the fact that revenues and profits keep growing rapidly. We rank Tesla (based on fundamental metrics) versus 20 top growth stocks sourced from the top 10 holdings of two popular active growth ETFs (Future Fu...
ARK Invest CEO Cathie Wood and her team have made yet another aggressive call about one of their key holdings, saying Thursday that Exact Sciences ( NASDAQ: EXAS ) can reach $140 per share by 2027. For comparison, EXAS traded near $49 a share after dipping 0.2% in Thursday's ...
Summary According to ARK’s research, Exact Sciences has been a pioneering force in the growing field of oncology testing and will likely remain so during the next five years. Exact’s competitive advantages include its commercial scale, brand recognition, deep regulatory ex...
Summary ARK Genomic Revolution ETF invests in small-cap and mid-cap companies engaged in genomic revolution, i.e., in the research of genomic sequencing, analysis, synthesis, or instrumentation. Alpha-generating stocks ARKG selects from time to time and backs for a longer time period ha...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Ivan Marc / Shutterstock.com Barely two weeks after doubling down on Tesla (NASDAQ: TSLA ) shares — purchasing TSLA stock on two separate occasions during the week of Dec. 21 — Ark Invest found...
Summary ARK Invest does great deep-dive research. Utilize their insights along with market timing considerations to generate alpha. The performance of ARKG is dictated mostly by interest rate decisions in the current environment. But underneath the macro layer, there are many promising ...
Medicare and Insurance Policy Updates in 2023 Will Improve Cancer Screening Access by Removing Patient Colonoscopy Cost Following a Positive Cologuard Test PR Newswire MADISON, Wis. , Dec. 20, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leadi...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Cosmos (NASDAQ: COSM ) stock is on the move Friday as the healthcare company undergoes a name change and a reverse stock split today. The name change saw the company moving from the Cosmos Hol...
Exact Sciences Presents First Time Data Detailing Ability to Predict Radiation Therapy Benefit in Breast Cancer Patients PR Newswire MADISON, Wis. , Dec. 9, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagn...
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...